Common Sensing and Welkin Health said last month that the companies are partnering to develop a digital diabetes management program designed to improve insulin adherence. The companies plan to craft a program that combines insulin dosing data collected from Common Sensing’s Gocap smart insulin pen with Welkin Health’s digital coaches to support patients with diabetes. […]
Diabetes
QuiO adds MedCrypt data security to Smartinjector pen
MedCrypt and QuiO said earlier this month that the companies are partnering to integrate MedCrypt’s data security software into QuiO’s Smartinjector devices. According to the agreement, MedCrypt will provide software security for QuiO’s Si One pen for specialty drugs and the Si Pen for diabetes patients. The companies plan to integrate the devices with software […]
Insulet touts Omnipod Horizon hybrid closed-loop system in patients with T1D
Insulet (NSDQ:PODD) touted data today from the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system in patients with Type 1 diabetes. Data from the study showed that the Omnipod automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe. The Billerica, Mass.-based company enrolled 24 patients with Type 1 diabetes […]
JDRF backs GluSense with $2m grant
GluSense said yesterday that it received a $2 million grant from the Juvenile Diabetes Research Foundation’s T1D fund for the company’s injectable glucose sensor. Israel-based GluSense, part of Rainbow Medical, is developing the Glyde continuous glucose monitor for patients with Type I diabetes. The device is injected under the skin and lasts for 1 year, […]
Update: Insulet opens manufacturing facility in Acton, Mass.
Insulet (NSDQ:PODD) said yesterday that it acquired a manufacturing facility in Acton, Mass. The Billerica, Mass.-based company said that its new facility will allow Insulet to more efficiently manufacture its OmniPod system compared to 4 of the company’s manufacturing lines at its contract manufacturer in China. The company anticipates the new facility will add hundreds of jobs in Massachusetts […]
Abbott touts association between monitoring and improved glucose control
Abbott (NYSE:ABT) touted results today from real-world use data for its FreeStyle Libre blood glucose monitoring system. The data showed that people using its FreeStyle Libre system to monitor their glucose levels spend less time in hypoglycemia or hyperglycemia and have improved average glucose levels. More than 50,000 diabetes patients using the FreeStyle Libre system checked […]
Medtech stories we missed: Feb. 10, 2017
From Glytec partnering to beat diabetes to Biolase, Gramercy Extremity Orthopedics and more getting FDA clearances, here are 7 recent medtech stories we missed this week, but were still worth mentioning. 1. BioTime proposes public offering of common stock Clinical-stage biotechnology company BioTech is intending to offer common stock shares in an underwritten public offering. BioTime focuses […]
Missouri University researchers use autograft harvesting to treat chronic wounds
Chronic wound sufferers were able to get skin grafts in an outpatient clinic—all through a Missouri University research team’s work. The researchers used the Acelity Cellutome Epidermal Harvesting System. It is an automated, precise and reproducible process that offers minimal pain and less donor-site trauma. It features suction microsomes that harvest epidermal micrografts automatically, eliminating the […]
Eli Lilly wins label expansion for Trulicity injection with basal insulin
Eli Lilly (NYSE:LLY) said today that the FDA approved label changes for its once-weekly Trulicity injection. The new label was updated to include use in combination with basal insulin for adults with Type 2 diabetes. The label update was based on results from a phase IIIb randomized clinical trial, Lilly said, which evaluated Trulicity as an […]
NIH launches pivotal trials for artificial pancreas
The National Institutes of Health said this week that it is funding 4 projects dedicated to testing fully automated artificial pancreas devices in patients with Type I diabetes. The race to develop an artificial pancreas met a milestone last year, after the FDA approved Medtronic’s (NYSE:MDT) hybrid model of an artificial pancreas – the 1st of its kind […]